drugset / Trial / NCT06744777

The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever

NCT06744777

Phase 3 Completed 284 enrolled Khyber Medical University Peshawar
RandomizedParallel-groupTriple-blindTreatment

Summary

This study investigates the comparative efficacy of standard treatment plus Ribavirin versus standard treatment alone in preventing clinically significant hemorrhage among patients diagnosed with dengue fever. It is a double-blind, randomized control trial aimed at determining whether the addition of Ribavirin improves clinical outcomes, particularly reducing bleeding events.

Timeline

Start
2024-12-17
Primary completion
2025-04-28
Completion
2025-05-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 15 mg/kg Oral